Medicines available at up to 90 percent discount under Janaushadhi Scheme

Published On 2024-08-29 08:45 GMT | Update On 2024-08-29 08:45 GMT

Gurugram: Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) is among the various schemes run by the central government to provide affordable treatment to the public. This scheme offers medicines at up to 90 per cent discount.

In this context, ANI visited the Jan Aushadhi warehouse in Gurugram, Haryana, to observe how these medicines are made available to the public.

Dr. Arunish Chawla, Secretary of the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, stated, "Jan Aushadhi is a flagship program of the Indian government. From the Red Fort, PM Modi announced that we will increase the number of Jan Aushadhi Kendras from 10,000 to 25,000 over the next three years. Jan Aushadhi Kendras are rapidly opening across the country, with over 13,000 currently operational.."

Ravi Dadhich, CEO of the Pharmaceuticals and Medical Devices Bureau of India (PMBI), explained that India has 10,000 manufacturing units across various states involved in the production of Janaushadhi medicines. He elaborated on the production chain, ensuring that the manufacturers are WHO-GMP certified to guarantee the highest quality standards.

"There are more than 10,000 manufacturing units across different states in India. We place orders for Janaushadhi medicines while ensuring that the manufacturers are WHO-GMP certified, so we receive the best quality medicines. Once the medicines meet the prescribed standards, they are supplied to the national-level Janaushadhi central warehouse," he said

He also mentioned that similar warehouses are located in Guwahati, Chennai, Bangalore, and Surat to serve different regions of the country.

"After receiving the medicines in this warehouse, we anonymize the details, concealing the manufacturer's information, and send them for retesting at NABL-accredited labs. Once we receive a certified report confirming their quality, we distribute them to different parts of the country, selling them through our 13,000 Janaushadhi centres," he added.

"These medicines are 50 per cent to 90 per cent cheaper than branded alternatives. The majority of the medicines are at least 50% cheaper, with some offering discounts of up to 90 per cent," he further explained.

Article Source : With inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Medicines available at up to 90 percent discount under Janaushadhi Scheme

Similar News

USFDA approves expanded indication for Takeda Vonvendi for adults, children with Von Willebrand Disease

Roche receives EU CE mark for Contivue for neovascular age-related macular degeneration

Drug Safety Alert: IPC Flags Adverse Reactions linked to Tranexamic acid and Metoclopramide

Virchow Biotech gets CDSCO panel nod to study Semaglutide for chronic weight management

SC Questions Effectiveness of UCPMP, Seeks Govt Clarification on Pharma Freebies

Dr Reddy's Labs API Mirfield facility gets 7 USFDA observations

CDSCO Panel Rejects Theon Pharma's Proposal for Empagliflozin, Linagliptin, Metformin FDC

Virchow Biotech Gets CDSCO Panel Nod for Semaglutide BE, Phase III Trials